belinostat

Also known as PXD-101, PXD101

Belinostat (trade name Beleodaq, previously known as PXD101) is a histone deacetylase inhibitor drug developed by TopoTarget for the treatment of hematological malignancies and solid tumors.

Key facts

Drug.N: 2
Drug.H: 14
Drug.IUPAC_name: (2E)-N-Hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide
Drug.image: Belinostat.svg
Drug.image_class: skin-invert-image
Drug.tradename: Beleodaq
Drug.pregnancy_US: D
Drug.legal_US: Rx-only
Drug.routes_of_administration: Intravenous (IV)
Drug.bioavailability: 100% (IV)
Drug.protein_bound: 92.9–95.8%
Drug.metabolism: UGT1A1
Drug.excretion: Urine
Drug.CAS_number: 866323-14-0
Drug.ATC_prefix: L01
Drug.ATC_suffix: XH04
Drug.PubChem: 6918638
Drug.DrugBank: DB05015

via Wikipedia infobox

Chemical data

Formula: C15H14N2O4S
Molecular weight: 318.3 g/mol
IUPAC name: (E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide
SMILES: C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)/C=C/C(=O)NO
InChIKey: NCNRHFGMJRPRSK-MDZDMXLPSA-N
XLogP: 1.7
Polar surface area: 104 Å²
H-bond donors: 3
H-bond acceptors: 5
Formal charge: 0

via PubChem

Drug data · ChEMBL

Max clinical phase: Approved
Molecule type: Small molecule
First approval: 2014
Admin. routes: parenteral
Indications: unspecified peripheral T-cell lymphoma, neoplasm, acute myeloid leukemia, mesothelioma

via ChEMBL · EBI

Research

396 papers

Belinostat.2012
Belinostat.2006
Belinostat Therapy and UGT1A1 Genotype.2012
Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015
Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2017

via PubMed

Wikidata facts

Has part: carbon
Mass: 318.067428
Has use: medication

Show 6 more facts

chemical formula: C₁₅H₁₄N₂O₄S
canonical SMILES: C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO
NCI Thesaurus ID: C48812
isomeric SMILES: O=C(/C=C/c1cccc(S(=O)(=O)Nc2ccccc2)c1)NO
subject has role: antineoplastic
Commons category: Belinostat

Sources (4)

via Wikidata · CC0

~1 min read

Encyclopedic overview

1 sections

Contents

References

Belinostat (trade name Beleodaq, previously known as PXD101) is a histone deacetylase inhibitor drug developed by TopoTarget for the treatment of hematological malignancies and solid tumors.

It was approved in July 2014 by the US FDA to treat peripheral T-cell lymphoma.

Excerpted from Wikipedia’s “belinostat” article, available under the CC BY-SA 4.0 licence.

Available in 9 languages

via Wikidata sitelinks · CC0